- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 05.10. | Hypha Labs, Inc.: Hypha Labs Targets Disruptive Mushroom Active Ingredient Production | 405 | ACCESS Newswire | Eight-Day Cycles and Potential 80% Cost Savings LAS VEGAS, NV / ACCESS Newswire / October 5, 2026 / The global functional mushroom market is estimated to reach $42.27 billion in 2026 and projected to... ► Artikel lesen | |
| 27.07. | Hypha Labs, Inc.: The Functional Mushroom Revolution Has Begun | 377 | ACCESS Newswire | Hypha Labs (OTCQB:FUNI) Is Building the Technology to Scale the Industry LAS VEGAS, NV / ACCESS Newswire / July 27, 2026 / Hypha Labs, Inc. (OTCQB:FUNI), a biotechnology company developing automated... ► Artikel lesen | |
| 13.07. | Hypha Labs, Inc.: Hypha Labs Sees State-by-State Psilocybin Reform Creating the Next Major Growth Opportunity | 295 | ACCESS Newswire | Company Believes Industry Is Following the Early Regulatory Path That Fueled the Cannabis Market LAS VEGAS, NV / ACCESS Newswire / July 13, 2026 / Hypha Labs, Inc. (OTCQB:FUNI), a biotechnology company... ► Artikel lesen | |
| 04.06. | Hypha Labs, Inc.: Hypha Labs Highlights Parallels Between Emerging Psychedelic Industry and Early Cannabis Market Expansion | 315 | ACCESS Newswire | State-Level Reform, Growing Public Acceptance, and Expanding Market Capitalizations Signal Potential Long-Term Industry Opportunity LAS VEGAS, NV / ACCESS Newswire / June 4, 2026 / Hypha Labs, Inc.... ► Artikel lesen | |
| 15.05. | Hypha Labs, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 27.04. | Hypha Labs, Inc.: Trump Psychedelic Executive Order Accelerates Industry Growth | 417 | ACCESS Newswire | Hypha Labs, Inc. (FUNI) Positioned to Lead with AI-Driven Production Technology LAS VEGAS, NV / ACCESS Newswire / April 27, 2026 / Hypha Labs, Inc. (OTCQB:FUNI), a biotechnology innovator focused on... ► Artikel lesen | |
| HYPHA LABS Aktie jetzt für 0€ handeln | |||||
| 09.04. | Hypha Labs, Inc. Announces Partnership with Mycology Resources, LLC | 531 | ACCESS Newswire | Companies Combine Technology, Cultivation, and Global Distribution LAS VEGAS, NV / ACCESS Newswire / April 9, 2026 / Hypha Labs, Inc. (OTCQB:FUNI), a biotechnology innovator in the functional mushroom... ► Artikel lesen |
7 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PEPGEN | 4,620 | +0,22 % | PepGen soars on promising early data for muscular dystrophy drug | ||
| PRAXIS PRECISION MEDICINES | 337,27 | -0,09 % | Praxis Precision Medicines, Inc. - 10-Q, Quarterly Report | ||
| DISC MEDICINE | 84,77 | +0,15 % | Disc Medicine auf der Guggenheim-Konferenz: Finanzstarker Vorstoß in die Vermarktungsphase | ||
| ARCUTIS BIOTHERAPEUTICS | 27,385 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| DYNE THERAPEUTICS | 17,920 | 0,00 % | Dyne Therapeutics, Inc. - 8-K, Current Report | ||
| ERASCA | 15,480 | 0,00 % | Tango Therapeutics, Inc.; Erasca, Inc.: Tango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015 | ||
| EDGEWISE THERAPEUTICS | 46,570 | +0,09 % | Edgewise Therapeutics Announces Productive End-of-Phase 2 Meeting with FDA for EDG-7500 in HCM; Phase 3 Protocol Features Tolerability-Based Dose Escalation Without Safety Echo Monitoring | - Following the End-of-Phase 2 meeting, Edgewise has submitted the STRATUS-HCM Phase 3 protocol with dose escalation guided by investigator assessment of tolerability -- STRATUS-HCM includes two independent... ► Artikel lesen | |
| COGENT BIOSCIENCES | 31,600 | -0,13 % | Cogent Biosciences auf Guggenheim-Konferenz: Marktstart rückt näher | ||
| TANGO THERAPEUTICS | 24,280 | -0,08 % | Jefferies raises Tango Therapeutics stock price target on trial data | ||
| ABSCI | 9,970 | 0,00 % | Absci auf der Guggenheim-Gesundheitskonferenz: Eigene Pipeline rückt in den Fokus | ||
| KYMERA THERAPEUTICS | 136,60 | -0,03 % | Kymera International Appoints Willson Ropp as Chief Executive Officer | Experienced specialty materials executive brings more than 30 years of leadership experience across global manufacturing, operational excellence, business integration, and long-term value... ► Artikel lesen | |
| BEAM THERAPEUTICS | 25,160 | +0,04 % | Jones Trading initiates Beam Therapeutics stock coverage with buy rating | ||
| ENLIVEN THERAPEUTICS | 51,29 | +0,18 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Business Update | Reached alignment with the FDA on the final design of the ENABLE-2 pivotal Phase 3 trial On track to initiate ENABLE-2 before year-end 2026 Strong balance sheet with $884 million in cash, cash equivalents... ► Artikel lesen | |
| JANUX THERAPEUTICS | 12,040 | 0,00 % | Janux reports phase 1 data for autoimmune drug candidate JANX011 | ||
| RECURSION PHARMACEUTICALS | 3,550 | 0,00 % | Recursion Pharmaceuticals (NDQ:RXRX): Why Is Nvidia An Investor? Because Its AI Platform Could Change Drug Discovery, Or Could It? |
HYPHA LABS INC gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu HYPHA LABS INC finden Sie auf Wallstreet Online.